TMDX - NASDAQ

TransMedics Group, Inc.

TMDX·NASDAQ

$69.69

+3.2%

HealthcareMedical - Devices

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.41B

EPS5.6000

P/E Ratio12.44

Earnings Date07/29/2026

1.07B

Assets

33%

3Y+285.0%

5Y+603.0%

10Y+1739.0%

595.27M

Total Liabilities

3Y+563.0%

5Y+1137.0%

10Y+2982.0%

473.10M

Total Equity

107%

3Y+152.0%

5Y+355.0%

10Y+1120.0%

TransMedics Group, Inc. Funding & Solvency Profile

TMDX · NASDAQ

Current Assets

Cash & Cash Equivalents488.37M

Net Receivables84.28M

Inventory48.88M

Other Current Assets16.25M

Total Current Assets638 M

Non-Current Assets

Property, Plant & Equipment332.81M

Goodwill & Intangible Assets13.50M

Long-Term Investments0.00

Other Non-Current Assets739.00K

Total Non-Current Assets334 M

Total Assets

1.07B

Financial Health Analysis

Current Ratio

7.14x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.26x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

548 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

60% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

TransMedics Group, Inc. Balance Sheet

TMDX • NASDAQ

TransMedics Group, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	488.4M	336.7M	394.8M	201.2M	25.6M	24.6M	20.1M	20.2M	11.9M	9.8M
Short-Term Investments	0.0	0.0	0.0	0.0	66.9M	101.1M	60.6M	0.0	12.7M	38M
Cash & Short-Term Investments	488.4M	336.7M	394.8M	201.2M	92.5M	125.6M	80.7M	20.2M	24.7M	47.8M
Net Receivables	84.3M	97.7M	63.6M	27.6M	5.9M	6.9M	6.6M	3.4M	925K	1.4M
Accounts Receivables	84.3M	97.7M	63.6M	27.6M	5.9M	6.9M	6.6M	3.4M	925K	1.4M
Inventory	48.9M	46.6M	44.2M	20.6M	14.9M	11.9M	11.2M	9.3M	8M	6.3M
Prepaids	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8M	477K	311K
Other Current Assets	16.3M	16.3M	8M	2.9M	5.5M	2.3M	1.5M	0.0	0.0	0.0
Total Current Assets	637.8M	497.2M	510.7M	252.3M	118.7M	146.8M	100M	34.8M	34M	55.9M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	332.8M	292.5M	180.5M	24.4M	15.7M	4.8M	4.8M	3.5M	2.5M	1.7M
Goodwill	11.5M	11.5M	12M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	1.9M	2.2M	2.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	13.5M	13.7M	14.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	500K	500K	0.0	500K	500K	500K	0.0
Tax Assets	83.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	739K	708K	562K	0.0	0.0	506K	6K	3.4M	6K	518K
Total Non-Current Assets	430.6M	306.9M	195.4M	24.9M	16.2M	5.3M	5.3M	7.4M	3M	2.2M
Total Assets	1.1B	804.1M	706M	277.1M	134.9M	152M	105.3M	42.2M	37M	58.1M
LIABILITIES
CURRENT LIABILITIES
Total Payables	10.4M	10.3M	12.7M	3.3M	6.7M	1.2M	7.2M	4.7M	3.5M	4.3M
Accounts Payable	10.4M	10.3M	12.7M	3.3M	6.7M	1.2M	7.2M	4.7M	3.5M	4.3M
Accrued Expenses	0.0	0.0	20.3M	9.8M	5.2M	4M	8.3M	7.2M	5M	4.7M
Short Term Debt	13.3M	2.7M	0.0	0.0	0.0	0.0	0.0	0.0	1.8M	0.0
Capital Lease Obligations (Current)	0.0	0.0	2M	1.4M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	2.9M	1.7M	2M	241K	250K	263K	166K	306K	239K	0.0
Other Current Liabilities	62.7M	45.2M	17.9M	8.8M	11.2M	6.4M	370K	655K	569K	488K
Total Current Liabilities	89.3M	59.9M	54.9M	23.7M	23.2M	11.9M	16.1M	12.6M	10.9M	9.5M
NON-CURRENT LIABILITIES
Long Term Debt	456.4M	509.3M	506.2M	58.7M	35.2M	34.7M	34.1M	33.7M	6.8M	8.4M
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	759K	1.1M	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-759K	-1.1M	0.0
Other Non-Current Liabilities	49.6M	0.0	0.0	0.0	0.0	1.6M	389K	759K	188M	1.4M
Total Non-Current Liabilities	506M	515.6M	513.9M	66.1M	43.8M	36.3M	34.5M	34.4M	194.8M	9.8M
Capital Lease Obligations	0.0	6.2M	9.7M	8.9M	8.6M	0.0	0.0	0.0	0.0	0.0
Total Liabilities	595.3M	575.5M	568.8M	89.8M	67M	48.1M	50.7M	47M	205.7M	19.3M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	186.5M	186.5M	187M
Common Stock	750.9M	697.2M	641.1M	666.3M	510.5M	502.2M	424.1M	331.2M	1K	1K
Additional Paid-In Capital	0.0	0.0	0.0	0.0	0.0	0.0	0.0	143.8M	143.6M	143.5M
Retained Earnings	-278M	-468.2M	-503.7M	-478.7M	-442.4M	-398.2M	-369.5M	-335.9M	-312.2M	-291.4M
Accumulated Other Comprehensive Income/Loss	124K	-364K	-199K	-225K	-188K	-95K	-2K	-101K	-149K	-417K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	898K	0.0	0.0
Total Stockholders' Equity	473.1M	228.6M	137.2M	187.4M	67.9M	103.9M	54.6M	-4.8M	-168.7M	38.8M
Total Equity	473.1M	228.6M	137.2M	187.4M	67.9M	103.9M	54.6M	-4.8M	-168.7M	38.8M
SUMMARY
Total Liabilities & Equity	1.1B	804.1M	706M	277.1M	134.9M	152M	105.3M	42.2M	37M	58.1M
Total Investments	0.0	0.0	0.0	500K	67.4M	101.1M	61.1M	500K	13.2M	38M
Total Debt	469.7M	518.3M	515.9M	67.6M	43.8M	34.7M	34.1M	33.7M	8.7M	8.4M
Net Debt	-18.7M	181.6M	121.1M	-133.6M	18.2M	10.1M	14.1M	13.4M	-3.3M	-1.4M
Shares Outstanding	34,174,325	34,174,325	34,174,325	34,174,325	34,174,325	34,174,325	34,174,325	34,174,325	34,174,325	34,174,325

SEC Filings

TMDX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 20, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 05, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	May 05, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 10, 2026	May 20, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 27, 2026	February 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 24, 2026	February 24, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 24, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 04, 2026	February 01, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 08, 2026	2026	View Filing
10-Q 10-Q 2025 Q3 Q3	October 29, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 124 filings

Related Guides

Blog Categories

Continue your TMDX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.